MINNEAPOLIS — February 21, 2018 — Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma (NHL) showed that survival at 4 years following allogeneic hematopoietic cell transplantation (HCT) for patients age 65 years and older is comparable to patients age 55 to 64 years. The study demonstrates that age alone should not be a determinant when considering HCT for patients with NHL. The study results will be presented in an oral session at the BMT Tandem Meetings on Saturday, February 24.
This multi-center study — conducted by researchers at the CIBMTR® (Center for International Blood and Marrow Transplant Research®) — compared the outcomes of 446 patients age 65 years and older with outcomes of 1,183 patients age 55-64 years who underwent allogeneic HCT for NHL from 2008 to 2015. Disease subtypes of NHL included follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma and mature T- or NK-cell lymphoma.
No significant differences were found in the 4-year overall survival (46% vs. 51%, p=0.07) and disease relapse/progression (42% vs. 41%, p=0.82) after allogeneic HCT for patients in the 65 and older age group (median age 68), compared to patients in the 55-64 age group (median age 60).
Article originally posted at